Skip to main content
. 2023 Sep 7;15(9):2293. doi: 10.3390/pharmaceutics15092293

Figure 6.

Figure 6

Cu-Based NMs synergizes PTT/PDT-induced cuproptosis. Increasing Cu levels in tumor cells can enhance NIR-responsive capability, cause cuproptosis, and synergize PTT/PDT tumor treatment.